SteadyMed Outlines Strategic Goals and Priorities for 2017 and Provides Update on Trevyent Launch Plans
SAN RAMON, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- SteadyMed Therapeutics Ltd. (NASDAQ:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery …